---
title: "Weekly Recap | CME +0.91%, record October contract volume"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304728495.md"
description: "CME (CME) gained 0.91% this week to close at $305.89, while the S&P 500 fell 2.68%, meaning the stock outperformed by roughly 3.59 percentage points. The week started with a modest rise to $306.24 on Monday, pulled back to $304.06 on Tuesday, then recovered to $308.27 on Wednesday. Thursday saw the week’s high of $312.80 before giving back gains, and Friday closed at $305.89. The overall pattern was a choppy week that ended with a late pullback from highs."
datetime: "2026-11-07T09:42:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304728495.md)
  - [en](https://longbridge.com/en/news/304728495.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304728495.md)
generator: "portal-rs"
---

# Weekly Recap | CME +0.91%, record October contract volume

## The Week

CME (CME) gained 0.91% this week to close at $305.89, while the S&P 500 fell 2.68%, meaning the stock outperformed by roughly 3.59 percentage points. The week started with a modest rise to $306.24 on Monday, pulled back to $304.06 on Tuesday, then recovered to $308.27 on Wednesday. Thursday saw the week’s high of $312.80 before giving back gains, and Friday closed at $305.89. The overall pattern was a choppy week that ended with a late pullback from highs.

## Key Events

CME reported record October average daily volume of 30 million contracts, up 15% year on year, with crypto contract ADV reaching $7.85 billion. The company also disclosed record market data revenue of $243 million last quarter and declared a quarterly dividend. Chief Commercial Officer Julie Winkler reported disposing of $3.08 million in common shares. On the regulatory front, CEO Duffy publicly said the CFTC’s approach is unsustainable and that prediction contracts on sports outcomes amount to gambling.

## Analyst Ratings

Among 18 covering institutions, 4 rate the stock buy, 5 rate it over, 6 rate it hold, 1 rates it under, 1 rates it sell, and 1 has no opinion. The consensus recommendation is buy, with a consensus target of $317.0625, about 3.65% above the recent price. Individual targets range from $227 to $367, showing wide disagreement. The stock ranks 8th within an industry group of 26 peers.

## The Week Ahead

Several US macro data points land next week: wholesale sales on Monday 9 November, and NFIB small business optimism, CPI and core CPI on Tuesday 10 November. CPI prints will be watched for any shift in the Fed policy outlook. CME’s Q4 FY2026 earnings are scheduled for pre-market on 10 February 2027, with estimates pointing to EPS of $2.8515 and revenue of $1.762 billion, still some way off.

## In Short

CME moved against a falling market this week while setting fresh volume records. The ratings picture leans positive, but target prices are widely spread. On the latest trading day, small-lot flow was a net seller while large and medium orders were small net buyers, suggesting different participants read the pace differently. The key read-through is whether CPI data shifts risk appetite and whether volume momentum can persist from a high base.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CME.US](https://longbridge.com/en/quote/CME.US.md)

## Related News & Research

- [CME Group 3Q Profit, Revenue Rise on Higher Derivatives Volume](https://longbridge.com/en/news/302560024.md)
- [Uniswap’s retail demand returns after 2 weeks of losses: Can UNI defend $6.80?](https://longbridge.com/en/news/301735342.md)
- [‘The Worst May Not Be Over,’ Says Investor About Rocket Lab Stock](https://longbridge.com/en/news/304905914.md)
- [House Democratic leader says lawmakers needs answers on Nvidia, wants China chip restrictions](https://longbridge.com/en/news/304905260.md)
- [Is Corning (GLW) Undervalued After Strong Earnings And Higher Guidance?](https://longbridge.com/en/news/304790245.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**